• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Cesare Gridelli, Francesco Perrone, +20 authors Vittorio Gebbia
  • Medicine
  • Journal of the National Cancer Institute
  • 2003 (First Publication: 5 March 2003)
  • BACKGROUND Vinorelbine prolongs survival and improves quality of life in elderly patients with advanced non-small-cell lung cancer (NSCLC). Some studies have also suggested that gemcitabine is wellExpand
  • Massimo Di Maio, Cesare Gridelli, +17 authors Francesco Perrone
  • Medicine
  • The Lancet. Oncology
  • 2005 (First Publication: 1 September 2005)
  • BACKGROUND Chemotherapy is the standard treatment for advanced non-small-cell lung cancer, and myelosuppression is a common side-effect. We aimed to assess whether haematological toxic effects couldExpand
  • G. P. Colucci, Roberto F Labianca, +17 authors Francesco Perrone
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2010 (First Publication: 1 April 2010)
  • PURPOSE Single-agent gemcitabine became standard first-line treatment for advanced pancreatic cancer after demonstration of superiority compared with fluorouracil. The Gruppo Italiano Pancreas 1Expand
  • Luigi Celio, Sergio Frustaci, +10 authors Emilio Bajetta
  • Medicine
  • Supportive Care in Cancer
  • 2010 (First Publication: 25 June 2010)
  • PurposeA phase III trial assessed the efficacy of palonosetron plus dexamethasone given once in preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV) following a broad range ofExpand
  • Stefano Cascinu, Rosa Rita Silva, +11 authors Giuseppina Catalano
  • Medicine
  • British Journal of Cancer
  • 1999 (First Publication: 1 July 1999)
  • SummaryIn a randomized clinical trial, gemcitabine (GEM) was more effective than 5-fluorouracil (5-FU) in advanced pancreatic cancer patients. GEM and 5-FU have different mechanisms of action andExpand
  • R Palumbo, F Sottotetti, +8 authors Antonio Bernardo
  • Medicine
  • Drug design, development and therapy
  • 2015 (First Publication: 15 April 2015)
  • Background A prospective, multicenter trial was undertaken to assess the activity, safety, and quality of life of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy inExpand
  • Alfredo Martini, E. Moro, Maria Adele Pacciarini, V. Tamassia, N Natale, Elena Piazza
  • Medicine
  • International journal of clinical pharmacology…
  • 1984
  • Eight cancer patients were given 4'-epi-DX and DX (70 mg/m2) by i.v. route at three-week intervals according to a randomized cross-over design. Blood samples were drawn at different intervals of timeExpand